319 related articles for article (PubMed ID: 25317578)
1. Modern prodrug design for targeted oral drug delivery.
Dahan A; Zimmermann EM; Ben-Shabat S
Molecules; 2014 Oct; 19(10):16489-505. PubMed ID: 25317578
[TBL] [Abstract][Full Text] [Related]
2. Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach.
Dahan A; Khamis M; Agbaria R; Karaman R
Expert Opin Drug Deliv; 2012 Aug; 9(8):1001-13. PubMed ID: 22703376
[TBL] [Abstract][Full Text] [Related]
3. [Research of oral prodrugs: opportunities and challenges].
Cao F; Ping QN; Chen J
Yao Xue Xue Bao; 2008 Apr; 43(4):343-9. PubMed ID: 18664193
[TBL] [Abstract][Full Text] [Related]
4. Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists.
Jana S; Mandlekar S; Marathe P
Curr Med Chem; 2010; 17(32):3874-908. PubMed ID: 20858214
[TBL] [Abstract][Full Text] [Related]
5. Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.
Gupta D; Varghese Gupta S; Dahan A; Tsume Y; Hilfinger J; Lee KD; Amidon GL
Mol Pharm; 2013 Feb; 10(2):512-22. PubMed ID: 23244438
[TBL] [Abstract][Full Text] [Related]
6. Prodrug based optimal drug delivery via membrane transporter/receptor.
Yang C; Tirucherai GS; Mitra AK
Expert Opin Biol Ther; 2001 Mar; 1(2):159-75. PubMed ID: 11727527
[TBL] [Abstract][Full Text] [Related]
7. A Minireview: Usefulness of Transporter-Targeted Prodrugs in Enhancing Membrane Permeability.
Murakami T
J Pharm Sci; 2016 Sep; 105(9):2515-2526. PubMed ID: 27321236
[TBL] [Abstract][Full Text] [Related]
8. Prodrug design targeting intestinal PepT1 for improved oral absorption: design and performance.
Zhang Y; Sun J; Sun Y; Wang Y; He Z
Curr Drug Metab; 2013 Jul; 14(6):675-87. PubMed ID: 23869811
[TBL] [Abstract][Full Text] [Related]
9. Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development.
Majumdar S; Duvvuri S; Mitra AK
Adv Drug Deliv Rev; 2004 Jun; 56(10):1437-52. PubMed ID: 15191791
[TBL] [Abstract][Full Text] [Related]
10. What should be considered on design of a colon-specific prodrug?
Jung Y; Kim YM
Expert Opin Drug Deliv; 2010 Feb; 7(2):245-58. PubMed ID: 20095945
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic Study on the Use of the l-Type Amino Acid Transporter 1 for Brain Intracellular Delivery of Ketoprofen via Prodrug: A Novel Approach Supporting the Development of Prodrugs for Intracellular Targets.
Puris E; Gynther M; de Lange ECM; Auriola S; Hammarlund-Udenaes M; Huttunen KM; Loryan I
Mol Pharm; 2019 Jul; 16(7):3261-3274. PubMed ID: 31180686
[TBL] [Abstract][Full Text] [Related]
12. Transporter targeted gatifloxacin prodrugs: synthesis, permeability, and topical ocular delivery.
Vooturi SK; Kadam RS; Kompella UB
Mol Pharm; 2012 Nov; 9(11):3136-46. PubMed ID: 23003105
[TBL] [Abstract][Full Text] [Related]
13. Prodrugs: effective solutions for solubility, permeability and targeting challenges.
Hu L
IDrugs; 2004 Aug; 7(8):736-42. PubMed ID: 15334306
[TBL] [Abstract][Full Text] [Related]
14. Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach.
Gupta SV; Gupta D; Sun J; Dahan A; Tsume Y; Hilfinger J; Lee KD; Amidon GL
Mol Pharm; 2011 Dec; 8(6):2358-67. PubMed ID: 21905667
[TBL] [Abstract][Full Text] [Related]
15. Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway.
Schumacher-Klinger A; Fanous J; Merzbach S; Weinmüller M; Reichart F; Räder AFB; Gitlin-Domagalska A; Gilon C; Kessler H; Hoffman A
Mol Pharm; 2018 Aug; 15(8):3468-3477. PubMed ID: 29976060
[TBL] [Abstract][Full Text] [Related]
16. Prodrugs: a challenge for the drug development.
Zawilska JB; Wojcieszak J; Olejniczak AB
Pharmacol Rep; 2013; 65(1):1-14. PubMed ID: 23563019
[TBL] [Abstract][Full Text] [Related]
17. Progress in drug delivery to the central nervous system by the prodrug approach.
Pavan B; Dalpiaz A; Ciliberti N; Biondi C; Manfredini S; Vertuani S
Molecules; 2008 May; 13(5):1035-65. PubMed ID: 18560328
[TBL] [Abstract][Full Text] [Related]
18. Advances in the use of prodrugs for drug delivery to the eye.
Taskar P; Tatke A; Majumdar S
Expert Opin Drug Deliv; 2017 Jan; 14(1):49-63. PubMed ID: 27441817
[TBL] [Abstract][Full Text] [Related]
19. Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system.
Lee JB; Zgair A; Malec J; Kim TH; Kim MG; Ali J; Qin C; Feng W; Chiang M; Gao X; Voronin G; Garces AE; Lau CL; Chan TH; Hume A; McIntosh TM; Soukarieh F; Al-Hayali M; Cipolla E; Collins HM; Heery DM; Shin BS; Yoo SD; Kagan L; Stocks MJ; Bradshaw TD; Fischer PM; Gershkovich P
J Control Release; 2018 Sep; 286():10-19. PubMed ID: 30016732
[TBL] [Abstract][Full Text] [Related]
20. Lipidic prodrug approach for improved oral drug delivery and therapy.
Markovic M; Ben-Shabat S; Keinan S; Aponick A; Zimmermann EM; Dahan A
Med Res Rev; 2019 Mar; 39(2):579-607. PubMed ID: 30320896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
